JPWO2021097131A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021097131A5 JPWO2021097131A5 JP2022526717A JP2022526717A JPWO2021097131A5 JP WO2021097131 A5 JPWO2021097131 A5 JP WO2021097131A5 JP 2022526717 A JP2022526717 A JP 2022526717A JP 2022526717 A JP2022526717 A JP 2022526717A JP WO2021097131 A5 JPWO2021097131 A5 JP WO2021097131A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- patient
- virus
- composition according
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 84
- 239000008194 pharmaceutical composition Substances 0.000 claims description 81
- 210000004027 cell Anatomy 0.000 claims description 72
- 241000700605 Viruses Species 0.000 claims description 55
- 101001125026 Homo sapiens Nucleotide-binding oligomerization domain-containing protein 2 Proteins 0.000 claims description 48
- 102100029441 Nucleotide-binding oligomerization domain-containing protein 2 Human genes 0.000 claims description 48
- 239000013598 vector Substances 0.000 claims description 32
- 239000003795 chemical substances by application Substances 0.000 claims description 30
- 239000013603 viral vector Substances 0.000 claims description 28
- 241000712907 Retroviridae Species 0.000 claims description 23
- 150000007523 nucleic acids Chemical class 0.000 claims description 22
- 230000000694 effects Effects 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 19
- 108020004707 nucleic acids Proteins 0.000 claims description 18
- 102000039446 nucleic acids Human genes 0.000 claims description 18
- 101710163270 Nuclease Proteins 0.000 claims description 17
- 108020005004 Guide RNA Proteins 0.000 claims description 11
- 239000003018 immunosuppressive agent Substances 0.000 claims description 10
- 210000000130 stem cell Anatomy 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 241001529453 unidentified herpesvirus Species 0.000 claims description 9
- 241000710929 Alphavirus Species 0.000 claims description 8
- 241000711573 Coronaviridae Species 0.000 claims description 8
- 241000709664 Picornaviridae Species 0.000 claims description 8
- 241000125945 Protoparvovirus Species 0.000 claims description 8
- 108700019146 Transgenes Proteins 0.000 claims description 8
- 239000003124 biologic agent Substances 0.000 claims description 8
- 239000003246 corticosteroid Substances 0.000 claims description 8
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 8
- 230000002459 sustained effect Effects 0.000 claims description 8
- 241000701161 unidentified adenovirus Species 0.000 claims description 8
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 7
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 7
- 241000714230 Avian leukemia virus Species 0.000 claims description 6
- 241000713704 Bovine immunodeficiency virus Species 0.000 claims description 6
- 241000714266 Bovine leukemia virus Species 0.000 claims description 6
- 108091033409 CRISPR Proteins 0.000 claims description 6
- 208000011231 Crohn disease Diseases 0.000 claims description 6
- 101710091045 Envelope protein Proteins 0.000 claims description 6
- 241000713730 Equine infectious anemia virus Species 0.000 claims description 6
- 241000714165 Feline leukemia virus Species 0.000 claims description 6
- 241000714475 Fujinami sarcoma virus Species 0.000 claims description 6
- 241000713673 Human foamy virus Species 0.000 claims description 6
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 6
- 241000714177 Murine leukemia virus Species 0.000 claims description 6
- 101710188315 Protein X Proteins 0.000 claims description 6
- 108020005067 RNA Splice Sites Proteins 0.000 claims description 6
- 241000710961 Semliki Forest virus Species 0.000 claims description 6
- 241000713820 Squirrel monkey retrovirus Species 0.000 claims description 6
- 102100021696 Syncytin-1 Human genes 0.000 claims description 6
- 241001223089 Tremovirus A Species 0.000 claims description 6
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 claims description 6
- 241000711975 Vesicular stomatitis virus Species 0.000 claims description 6
- 238000010354 CRISPR gene editing Methods 0.000 claims description 5
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims description 5
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 claims description 5
- 102100022338 Integrin alpha-M Human genes 0.000 claims description 5
- 102100025136 Macrosialin Human genes 0.000 claims description 5
- 230000003750 conditioning effect Effects 0.000 claims description 5
- 238000010253 intravenous injection Methods 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 241001664176 Alpharetrovirus Species 0.000 claims description 4
- 241000713756 Caprine arthritis encephalitis virus Species 0.000 claims description 4
- 241001663880 Gammaretrovirus Species 0.000 claims description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 4
- 241001529934 Simian T-lymphotropic virus 3 Species 0.000 claims description 4
- 241001492404 Woodchuck hepatitis virus Species 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 4
- 229960001334 corticosteroids Drugs 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 230000035772 mutation Effects 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 230000001124 posttranscriptional effect Effects 0.000 claims description 4
- 241000714232 Avian carcinoma virus Species 0.000 claims description 3
- 241000713851 Avian sarcoma virus CT10 Species 0.000 claims description 3
- 241000167854 Bourreria succulenta Species 0.000 claims description 3
- 241000702421 Dependoparvovirus Species 0.000 claims description 3
- 241000711798 Rabies lyssavirus Species 0.000 claims description 3
- 241000785681 Sander vitreus Species 0.000 claims description 3
- 235000019693 cherries Nutrition 0.000 claims description 3
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 3
- 238000001839 endoscopy Methods 0.000 claims description 3
- 210000005260 human cell Anatomy 0.000 claims description 3
- 230000001861 immunosuppressant effect Effects 0.000 claims description 3
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 3
- 208000019399 Colonic disease Diseases 0.000 claims description 2
- 101600119072 Homo sapiens Nucleotide-binding oligomerization domain-containing protein 2 (isoform 1) Proteins 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 102300033867 Nucleotide-binding oligomerization domain-containing protein 2 isoform 1 Human genes 0.000 claims description 2
- 229960002170 azathioprine Drugs 0.000 claims description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 2
- 238000002052 colonoscopy Methods 0.000 claims description 2
- 230000009266 disease activity Effects 0.000 claims description 2
- 230000003628 erosive effect Effects 0.000 claims description 2
- 230000009760 functional impairment Effects 0.000 claims description 2
- 230000006801 homologous recombination Effects 0.000 claims description 2
- 238000002744 homologous recombination Methods 0.000 claims description 2
- 230000001771 impaired effect Effects 0.000 claims description 2
- 229960000598 infliximab Drugs 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims description 2
- 230000004777 loss-of-function mutation Effects 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- 230000001483 mobilizing effect Effects 0.000 claims description 2
- 230000002085 persistent effect Effects 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 241000713824 Rous-associated virus Species 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 230000000415 inactivating effect Effects 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- 241000282693 Cercopithecidae Species 0.000 description 4
- 241000150288 Sin Nombre orthohantavirus Species 0.000 description 4
- 241000713666 Lentivirus Species 0.000 description 3
- 210000003995 blood forming stem cell Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 2
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 208000000389 T-cell leukemia Diseases 0.000 description 2
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 2
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 1
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 1
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 1
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 1
- 241001164823 Adeno-associated virus - 7 Species 0.000 description 1
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 1
- 241000649045 Adeno-associated virus 10 Species 0.000 description 1
- 108700004991 Cas12a Proteins 0.000 description 1
- 229920002491 Diethylaminoethyl-dextran Polymers 0.000 description 1
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000001400 myeloablative effect Effects 0.000 description 1
- 210000001167 myeloblast Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962934345P | 2019-11-12 | 2019-11-12 | |
| US62/934,345 | 2019-11-12 | ||
| PCT/US2020/060288 WO2021097131A1 (fr) | 2019-11-12 | 2020-11-12 | Compositions et méthodes de traitement ou de prévention de la maladie de crohn |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023507885A JP2023507885A (ja) | 2023-02-28 |
| JPWO2021097131A5 true JPWO2021097131A5 (fr) | 2023-11-20 |
Family
ID=75912891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022526717A Pending JP2023507885A (ja) | 2019-11-12 | 2020-11-12 | クローン病の治療または予防のための組成物及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220370509A1 (fr) |
| EP (1) | EP4058043A4 (fr) |
| JP (1) | JP2023507885A (fr) |
| CN (1) | CN115087455A (fr) |
| AU (1) | AU2020383510A1 (fr) |
| CA (1) | CA3160799A1 (fr) |
| WO (1) | WO2021097131A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114958917A (zh) * | 2022-06-21 | 2022-08-30 | 赛业（苏州）生物科技有限公司 | 一种克罗恩病小鼠动物模型的构建方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005115135A2 (fr) * | 2004-04-09 | 2005-12-08 | The Regents Of The University Of California | Modele murin de la maladie de crohn et methode de mise au point d'agents therapeutiques specifiques |
| EP1883708A4 (fr) * | 2005-04-29 | 2010-03-24 | Genizon Biosciences Inc | Carte genetique des genes humains associes a la maladie de crohn |
| GB0603427D0 (en) * | 2006-02-21 | 2006-04-05 | Ucl Biomedica Plc | IL-8 Therapy |
| EP2049691A4 (fr) * | 2006-07-26 | 2010-06-16 | Genizon Biosciences Inc | Gène de susceptibilité à la maladie de crohn |
| WO2008070564A1 (fr) * | 2006-12-01 | 2008-06-12 | The Government Of The U.S.A, As Represented By The Secretary, Departmentof Health And Human Services | Utilisations du dipeptide muramyle (mdp) dans le traitement de l'inflammation |
| US20120046329A1 (en) * | 2010-08-10 | 2012-02-23 | Sanford-Burnham Medical Research Institute | Modulators of nod1 and nod2 signaling, methods of identifying modulators of nod1 and nod2 signaling, and uses thereof |
| US9408873B2 (en) * | 2010-08-23 | 2016-08-09 | Kang Stem Biotech Co., Ltd. | Pharmaceutical composition comprising stem cells treated with NOD2 agonist or culture thereof for prevention and treatment of immune disorders and inflammatory diseases |
| WO2013125899A1 (fr) * | 2012-02-22 | 2013-08-29 | 주식회사 강스템홀딩스 | Composition pour prévention ou traitement de maladies immunitaires ou inflammatoires, contenant des cellules souches comme principe actif |
| MA40406A (fr) * | 2014-07-28 | 2016-02-04 | Nogra Pharma Ltd | Procédés et compositions de diagnostic et de traitement des maladies inflammatoires chroniques de l'intestin |
| TW201717968A (zh) * | 2015-07-14 | 2017-06-01 | 春季銀行製藥公司 | 誘導ｒｉｇ－ｉ和其他模式辨識受體之化合物及組成物 |
| MA54792A (fr) * | 2018-03-09 | 2021-12-01 | Avrobio Inc | Compositions et méthodes pour le traitement de la maladie de parkinson |
-
2020
- 2020-11-12 AU AU2020383510A patent/AU2020383510A1/en active Pending
- 2020-11-12 US US17/771,524 patent/US20220370509A1/en active Pending
- 2020-11-12 JP JP2022526717A patent/JP2023507885A/ja active Pending
- 2020-11-12 CN CN202080089510.4A patent/CN115087455A/zh active Pending
- 2020-11-12 EP EP20887937.9A patent/EP4058043A4/fr active Pending
- 2020-11-12 CA CA3160799A patent/CA3160799A1/fr active Pending
- 2020-11-12 WO PCT/US2020/060288 patent/WO2021097131A1/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gardlik et al. | Vectors and delivery systems in gene therapy | |
| JP4117023B2 (ja) | 組換えウイルスベクター系 | |
| ES2460947T3 (es) | Producción estable de vectores lentivirales | |
| US6218186B1 (en) | HIV-MSCV hybrid viral vector for gene transfer | |
| EP1958648A1 (fr) | Procede therapeutique visant les troubles de la coagulation sanguine | |
| IL110182A (en) | A retroviral issue for transferring genes and inserting them for medical purposes into eukaryotic cells | |
| WO1999015677A1 (fr) | Procede de transfert de gene utilisant bcl2 et compositions utiles a cet effet | |
| Miyake et al. | Stable integration of human immunodeficiency virus-based retroviral vectors into the chromosomes of nondividing cells | |
| Bertran et al. | Recombinant adeno-associated virus-mediated high-efficiency, transient expression of the murine cationic amino acid transporter (ecotropic retroviral receptor) permits stable transduction of human HeLa cells by ecotropic retroviral vectors | |
| Mergia et al. | The efficiency of simian foamy virus vector type-1 (SFV-1) in nondividing cells and in human PBLs | |
| US20230365996A1 (en) | Replacement of rag1 for use in therapy | |
| Douglas et al. | Efficient human immunodeficiency virus-based vector transduction of unstimulated human mobilized peripheral blood CD34+ cells in the SCID-hu Thy/Liv model of human T cell lymphopoiesis | |
| Hanawa et al. | High-level erythroid lineage-directed gene expression using globin gene regulatory elements after lentiviral vector-mediated gene transfer into primitive human and murine hematopoietic cells | |
| US20220218844A1 (en) | Gene therapy vectors for infantile malignant osteopetrosis | |
| JPWO2021097131A5 (fr) | ||
| CN116635523A (zh) | 用于疗法中的rag1的替代物 | |
| WO2008136656A1 (fr) | Procédés perfectionnés et moyens pour l'administration de gènes lentiviraux | |
| Matuskova et al. | Retroviral vectors in gene therapy | |
| JP7197901B2 (ja) | Ｈｕｎｔｅｒ症候群の遺伝子治療に使用されるベクタープラスミド、レンチウイルスベクターシステム、細胞、及び、細胞製剤 | |
| TW202129002A (zh) | 用於myh7關聯之心肌病之基因療法組合物及治療 | |
| Maina et al. | Optimization of recombinant adeno-associated viral vectors for human β-globin gene transfer and transgene expression | |
| WO2017156057A1 (fr) | Construction rétrovirale contenant un acide nucléique insensible à let-7 codant pour hmga2 et ses procédés d'utilisation | |
| Еpifanova et al. | Viral Vectors for Delivering Gene Material into Cells and Their Application in Neurobiology | |
| Klein | Advances in viral vector design: Tissue-and cell-type specific promoters can improve the safety and efficacy of lentiviral gene therapy | |
| AU2021202657A1 (en) | Polynucleotide |